2017 IMPAACT Annual Meeting Tuberculosis Scientific Committee Presentations

Tuberculosis Scientific Committee

Tuesday, 30 May

Welcome and Overview of Tuberculosis Scientific Agenda

Anneke Hesseling

Tuberculosis Prevention and Treatment Study Updates

PHOENIx (A5300/IMPAACT 2003): Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design


Amita Gupta

IMPAACT 2001: Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection


Jyoti Mathad

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents with MDR-TB Disease


Anneke Hesseling

IMPAACT 2005: A Phase I/II Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-infected and HIV-uninfected Children with MDR-TB


Ethel Weld

The Future of MDR-TB Treatment in Children

SMaRT Kids, the Adult MDR-TB Trials Landscape and Moving Pediatric TB Trials Forward


Tony Garcia-Prats

Emerging Data on Delaminid Pharmacokinetics and Safety in Children with MDR-TB

Jeffrey Hafkin

Using Pharmacokinetic Modelling to Evaluate Novel TB Drugs in Children More Efficiently: Experiences from BDQ CRUSH, P1108 and IMPAACT 2005


Elin Svensson

Update on Phenotypic and NGS-based Advances for Drug Susceptibility Testing and Their Use in Context of Clinical Trials


Marco Schito

Quantification of Circulating Mtb Antigen Peptides for Rapid Diagnosis and Treatment Monitoring


Tony Hu

Novel Blood-based Biomarkers for Pediatric TB

Jeff Tornheim
Mandar Paradkar